Eduovisual
Perioperative & Surgical Care
Pancreatic surgery: Whipple complications
— POD 0–2: bleeding, hemodynamic instability, MI, atelectasis
— POD 3–7: postoperative pancreatic fistula (POPF), delayed gastric emptying (DGE), intra-abdominal abscess, bile leak
— POD 7–21: sentinel bleed/pseudoaneurysm rupture, sepsis, anastomotic stricture, chyle leak
— Late (months–years): exocrine/endocrine insufficiency, marginal ulcer, biliary stricture, recurrence
Step 3 management: On any post-Whipple patient with new tachycardia or fever after POD 3, the reflex order set is drain fluid amylase + lipase, CBC, lactate, CT abdomen/pelvis with IV contrast, and a surgical reconsult — do not anchor on "ileus" or "atelectasis" until POPF, bleeding, and abscess are excluded.
Board pearl: The mortality of an isolated Whipple is low, but mortality of a Whipple complicated by post-pancreatectomy hemorrhage from a pseudoaneurysm approaches 30–50% — the index complication often is not what kills the patient.
— Presents POD 3–7 with cloudy/brownish drain output, fever, leukocytosis, ileus, or failure to advance diet.
— ISGPS definition: drain fluid amylase >3× serum upper limit on or after POD 3.
— Graded: Biochemical leak (no clinical impact, formerly Grade A), Grade B (change in management — antibiotics, prolonged drain, IR drainage, NPO), Grade C (reoperation, organ failure, or death).
— Inability to tolerate solid diet by POD 7, persistent NG output >500 mL/day, or NG reinsertion.
— Grade A: NG 4–7 days; Grade B: 8–14 days; Grade C: >14 days or reinsertion after POD 7.
— Early (<24 h): technical bleed, anticoagulation issue.
— Late (>24 h): nearly always erosion of a peripancreatic vessel (GDA stump, hepatic artery) from an underlying POPF or abscess — often heralded by a "sentinel bleed" (small herald hematemesis or blood from drain hours to days before catastrophic rupture).
Key history to elicit: preop neoadjuvant therapy (softens pancreas → ironically lowers POPF risk vs. soft non-irradiated gland), pancreatic duct size (<3 mm = high POPF risk), texture (soft gland = high risk), preop biliary stenting (raises infection risk), and comorbid diabetes (affects endocrine prognosis).
Board pearl: A "sentinel bleed" — even a small amount of blood in the drain or via NG tube on POD 5–14 — is a surgical emergency. Obtain urgent CT angiography; do not wait for hemodynamic collapse, because the next bleed from a hepatic artery pseudoaneurysm can be exsanguinating within minutes.
— Persistent HR >100 after POD 2 despite adequate analgesia and volume = occult complication until proven otherwise.
— New fever curve after POD 3 (not POD 1 atelectasis) suggests POPF, abscess, line infection, or C. difficile.
— Narrowing pulse pressure or orthostasis → think hemorrhage or sepsis from contained leak.
— Disproportionate pain, peritonitis, or rigidity → leak with peritonitis or ischemic bowel.
— Bulging, erythematous wound with serosanguinous drainage → fascial dehiscence or surgical site infection; gentle probing may reveal evisceration risk.
— Drain output: track volume, color, and character daily. Cloudy/turbid = POPF or infected collection; bilious green = HJ leak; bloody = PPH; milky = chyle leak (especially after enteral feeds started).
CCS pearl: On the CCS interface, after a Whipple, advance the clock in 2–4 hour intervals during PODs 0–2 and 6–12 hour intervals thereafter. Re-examine and recheck vitals at each interval. If HR climbs or drain character changes, the correct next orders are: vitals q1h, type & crossmatch 2–4 units PRBC, CBC, BMP, lactate, drain fluid amylase, and CT angiogram abdomen/pelvis — before you transfuse blindly or order more morphine.
Key distinction: POD 1 fever = atelectasis/SIRS response (low yield workup); POD 4–7 fever with tachycardia = POPF or abscess until ruled out by drain amylase and CT.
— Rising WBC after POD 3 or a "second hit" leukocytosis → infectious complication.
— Rising bilirubin/ALP after initial decline → HJ stricture or edema.
— Hgb drop >2 g/dL without obvious source → CT angiogram.
— POD 3 drain amylase ≤3× serum upper limit (and low volume) → safe early drain removal POD 3–5 reduces complications (multiple RCTs).
— POD 3 drain amylase >3× serum upper limit → POPF; do not remove drain; consider somatostatin analogue, hold advancement of diet, image if febrile.
— Looks for: peripancreatic fluid collection, free air, abscess, pseudoaneurysm (arterial-phase blush), biloma, bowel ischemia, portal vein thrombosis.
— Add CT angiography if any concern for PPH or sentinel bleed.
Board pearl: A falling Hgb plus rising drain amylase plus a "sentinel" trickle of blood in the drain = arterial pseudoaneurysm eroded by pancreatic juice — the most dangerous post-Whipple constellation. Go directly to CT angiography and call IR; do not delay for endoscopy.
Step 3 management: Don't reflex-order an MRCP for early postop fever — it is slow and adds little; contrast CT is faster, more sensitive for collections and vascular complications.
— Identifies bleeding source (GDA stump, common/proper hepatic artery, splenic artery) and guides IR embolization.
— Negative CTA with ongoing bleeding → proceed to catheter angiography, which is both diagnostic and therapeutic.
— Percutaneous transhepatic cholangiography (PTC) with biliary drain — preferred route for HJ stricture or leak management.
— Balloon-enteroscopy-assisted ERCP in select centers.
— Should be performed cautiously in early postop period; coordinate with surgical team to avoid anastomotic disruption.
Key distinction: Post-Whipple, when you see "jaundice + cholangitis at 6 months", the access route is PTC, not ERCP, because the ampulla is gone. This is a favorite distractor on Step 3.
Board pearl: Pseudoaneurysm on CTA = immediate IR embolization (coil/covered stent of hepatic artery). Open reoperation in an inflamed, hostile abdomen has worse outcomes than endovascular control.
— Gland texture (soft vs. firm) — soft = highest risk
— Pathology (non-pancreatic/non-ampullary cancers, like duodenal/ampullary, are higher risk)
— Pancreatic duct diameter (<3 mm = high risk)
— Intraoperative blood loss
— Biochemical leak (drain amylase elevated, asymptomatic): continue drain, observe, advance diet cautiously.
— Grade B POPF: NPO or low-fat diet, octreotide (controversial), broad-spectrum antibiotics if febrile, IR drainage of undrained collections, prolonged drain.
— Grade C POPF: ICU, source control via reoperation (completion pancreatectomy in extremis) or wide drainage; high mortality.
— DGE: rule out mechanical cause with UGI/EGD, NG decompression, prokinetics (erythromycin 200 mg IV q8h or metoclopramide), nutritional support via NJ tube or TPN if prolonged.
— PPH (late): CTA → IR embolization first-line; surgery only if endovascular fails or unstable.
— Bile leak: percutaneous drainage of collection + PTC with internal-external biliary drain.
— Chyle leak: low-fat or medium-chain triglyceride diet; if high output, NPO + TPN ± octreotide.
Step 3 management: Octreotide as prophylaxis for POPF is not routinely recommended, but pasireotide has RCT support in high-risk glands at select centers. Don't pick "octreotide for everyone" — pick selective use in high FRS gland + soft texture.
Board pearl: "Drains in, drains out by POD 3–5 if amylase low" — early removal is now standard of care and reduces infections, contrary to the older "leave drains until eating" doctrine.
— Single-dose preop: cefoxitin or piperacillin-tazobactam (covers biliary flora, especially in patients with preop biliary stent — ~80% have colonized bile).
— Redose intraop if case >3–4 hours or EBL >1.5 L.
— Do not continue postop prophylaxis beyond 24 h (Surgical Care Improvement Project / SCIP measure).
— Multimodal opioid-sparing: scheduled acetaminophen, NSAIDs (cautiously, weigh AKI/bleed risk), gabapentin, epidural or transversus abdominis plane (TAP) block.
— Avoid prolonged opioids → worsen DGE/ileus.
Board pearl: Extended 28-day post-discharge enoxaparin for abdominal/pelvic cancer surgery is a frequently tested Step 3 quality metric — do not stop heparin at discharge.
— Percutaneous drainage of POPF-related collections and abscesses (CT or US-guided pigtail catheter).
— Angioembolization for PPH/pseudoaneurysm: coil embolization of GDA stump or covered stent across hepatic artery to preserve hepatic flow (critical — hepatic artery sacrifice risks liver/HJ ischemia).
— PTC for HJ leak/stricture: internal-external biliary drain decompresses biliary tree, allows leak healing, and provides access for later balloon dilation of strictures.
— EGD for marginal ulcer hemorrhage at GJ (clips, epinephrine, thermal coagulation).
— Pancreatic duct stenting via balloon enteroscopy for PJ leak in select centers.
— Uncontrolled hemorrhage failing IR.
— Grade C POPF with sepsis/organ failure → wide drainage, disconnection of PJ, or completion pancreatectomy (salvage; ~30–50% mortality, lifelong brittle diabetes).
— Anastomotic dehiscence with peritonitis.
— Fascial dehiscence/evisceration.
— Bowel ischemia or internal hernia (late).
— Intraop placement of feeding jejunostomy in selected high-risk patients enables early enteral feeding if oral intake delayed.
— Avoid blind NJ tube placement near fresh anastomoses; use fluoroscopy.
CCS pearl: For a hypotensive post-Whipple patient with hematemesis on POD 10: (1) NS bolus + 2 units PRBC, (2) type & cross 4 more, (3) call IR for emergent angiography, (4) NPO, (5) PPI drip, (6) ICU transfer. Do not send to OR first — endovascular control is faster and morbidity is lower.
Board pearl: Preserving hepatic arterial flow during embolization is critical; bare-metal coils of the proper hepatic artery can necrose the HJ and cause biliary catastrophe — covered stents are preferred when feasible.
— Whipple is increasingly performed in octogenarians; biological > chronological age. Use frailty assessment (e.g., Clinical Frailty Scale, 5-item modified frailty index).
— Higher risk of: delirium (20–40%), DGE, cardiopulmonary complications, failure to rescue from POPF.
— Perioperative geriatric co-management reduces delirium and LOS — Step 3 favors multidisciplinary care.
— Avoid benzodiazepines, anticholinergics, meperidine; minimize tethers (Foley, lines) early.
— Nutritional optimization preop (prealbumin, albumin, weight loss >10% = high risk) — refer to dietitian; consider preop oral nutritional supplements.
— Higher AKI risk postop from contrast, NSAIDs, aminoglycosides, hypoperfusion.
— Renally dose enoxaparin (CrCl <30: 30 mg daily), piperacillin-tazobactam, fluconazole, gabapentin.
— Avoid NSAIDs for analgesia.
— Use isotonic crystalloids judiciously — over-resuscitation worsens anastomotic edema and DGE; under-resuscitation worsens AKI. Goal-directed therapy with stroke volume variation when available.
— Cirrhosis (even Child A) is a relative contraindication for Whipple — markedly elevated mortality due to portal hypertension, coagulopathy, ascites.
— Preop assessment with MELD score; MELD >10 dramatically increases mortality.
— Preop biliary drainage (PTC or ERCP stent) is indicated only if cholangitis, severe pruritus, malnutrition, or neoadjuvant therapy planned — not routine, as routine stenting increases infectious complications.
Step 3 management: In an 82-year-old with resectable pancreatic head cancer, the right answer is rarely "deny surgery based on age alone" — it's comprehensive geriatric assessment + frailty scoring + shared decision-making at a high-volume center.
Key distinction: Routine preop biliary stenting increases wound infections and POPF; reserve for specific indications.
— Pancreatic head cancer in pregnancy is extremely rare; Whipple has been performed in second trimester for select cases.
— Multidisciplinary planning with MFM, oncology, surgery; delay to postpartum if oncologically feasible.
— Avoid teratogens (methotrexate, certain chemotherapeutics); FOLFIRINOX is contraindicated in pregnancy.
— Indications: solid pseudopapillary neoplasm (Frantz tumor) of pancreatic head in adolescents, pancreatoblastoma, trauma with unreconstructable head injury.
— Long-term concerns dominate: exocrine and endocrine insufficiency for life, growth, bone health.
— Lifelong PERT, fat-soluble vitamin (ADEK) supplementation, glucose monitoring.
— Risk factors: smoking, chronic pancreatitis, hereditary syndromes (BRCA1/2, Lynch, Peutz-Jeghers, familial atypical multiple mole melanoma/CDKN2A, hereditary pancreatitis/PRSS1), new-onset DM after age 50, obesity.
— African American patients have higher incidence and mortality; access disparities to high-volume centers are a tested health systems point.
— Germline testing recommended for all newly diagnosed pancreatic ductal adenocarcinoma (NCCN) — affects family screening and PARP inhibitor eligibility (olaparib for BRCA-mutated).
— Loss of both insulin and glucagon → brittle, hypoglycemia-prone diabetes.
— Concurrent exocrine insufficiency complicates glycemic control (malabsorption-related lows).
— Endocrinology referral; basal-bolus insulin typical; metformin/SUs less useful.
Board pearl: New-onset diabetes in an adult >50 with weight loss should prompt evaluation for pancreatic cancer — a tested presentation. Order CA 19-9 + cross-sectional imaging (CT pancreas protocol).
Step 3 management: Refer all pancreatic adenocarcinoma patients for germline genetic testing regardless of family history.
— POPF (15–25%); DGE (20–40%); bile leak (3–8%); PPH (5–15%); intra-abdominal abscess (10–15%); wound infection (10–20%); fascial dehiscence (1–3%); anastomotic stricture (early HJ edema).
— Chyle leak (1–5%) — milky drain output, especially after fatty enteral feeds initiated.
— Portal vein thrombosis or stenosis after vein resection/reconstruction.
— AKI, pneumonia, atelectasis, PE/DVT, MI, atrial fibrillation, ileus, C. difficile, delirium, line sepsis.
— Exocrine pancreatic insufficiency (~50–80%): steatorrhea, weight loss, fat-soluble vitamin deficiency → PERT.
— Endocrine insufficiency / type 3c DM (~20–40%): brittle glycemic control.
— HJ stricture (3–10%): recurrent cholangitis, jaundice → PTC dilation.
— GJ marginal ulcer: epigastric pain, GI bleed → PPI, H. pylori testing, smoking cessation.
— Recurrent pancreatitis in remnant gland.
— Internal hernia / SBO through mesenteric defects.
— Bile reflux gastritis.
— Cancer recurrence: local (peripancreatic), hepatic, peritoneal, pulmonary — most within 2 years.
— Sustained weight loss, sarcopenia, bone density loss from vitamin D malabsorption — DEXA at 1 year.
Board pearl: Steatorrhea after Whipple is not "normal recovery" — it's pancreatic exocrine insufficiency requiring PERT titration (start 40,000–50,000 lipase units per meal, half-dose with snacks; uptitrate to symptom control).
Key distinction: "DGE" is a diagnosis of exclusion — first rule out mechanical obstruction, anastomotic stricture, intra-abdominal collection, and electrolyte derangement before labeling functional DGE.
— Hemodynamic instability (SBP <90, HR >120 sustained, lactate >2.5).
— Active hemorrhage (frank blood per drain/NG, Hgb drop >2 g/dL).
— Sepsis with organ dysfunction (qSOFA ≥2, vasopressor need).
— Respiratory failure (PaO2/FiO2 <300, increased work of breathing).
— AKI requiring CRRT, hyperkalemia, severe acidosis.
— Altered mental status with concern for sepsis or stroke.
— Surgery: any new bleeding, peritonitis, evisceration, suspected leak.
— Interventional radiology: undrained collection >3–4 cm, pseudoaneurysm, biloma.
— Gastroenterology: marginal ulcer bleed, late HJ/PJ leak, EGD needs.
— Infectious disease: persistent bacteremia, Candida in abdominal cultures, resistant organisms from stent biliary colonization.
— Cardiology: postop MI, new arrhythmia, decompensated HF.
— Nephrology: AKI not responding to volume optimization, renal replacement need.
— Nutrition: prolonged NPO >5–7 days, malnutrition risk → TPN or NJ tube.
— Geriatrics: delirium, frailty co-management.
— Palliative care: irreversible Grade C POPF, recurrent unresectable disease, goals-of-care.
CCS pearl: On CCS, if you encounter a post-Whipple patient on the ward with sentinel bleed or peritonitis, the correct sequence is: transfer to ICU, NPO, type & cross, IV access × 2, broad-spectrum antibiotics, consult surgery and IR simultaneously, CTA. Skipping ICU transfer or delaying IR consult will lower your score.
Step 3 management: Use the 30-day readmission rate as a quality metric — robust outpatient follow-up at 2 weeks post-discharge is the right answer for "what reduces readmission."
— POPF: drain amylase >3× serum; cloudy/brownish drain; treat with continued drainage, antibiotics if Grade B, IR for undrained collections.
— Bile leak (HJ): bilious drain; drain bilirubin >3× serum; HIDA or MRCP confirms; PTC drain definitive.
— Anastomotic dehiscence (GJ/DJ): peritonitis, free air on CT, frank enteric content in drain; reoperation usually required.
— Intra-abdominal abscess: rim-enhancing collection on CT; IR drainage + antibiotics.
— Pseudoaneurysm/PPH: sentinel bleed, falling Hgb, CTA blush; IR embolization.
— Chyle leak: milky drain after enteral feeds; triglycerides >110; low-fat/MCT diet, octreotide, NPO/TPN if severe.
— Portal vein thrombosis: variceal bleed, ascites, transaminitis; CT venous phase; anticoagulate if no active bleed.
— Wound infection / fasciitis: erythema, purulent drainage, crepitus (necrotizing); incision and drainage, broad antibiotics.
— DGE: large NG output, no leak on imaging; prokinetics, NJ feeds.
— Mechanical SBO from internal hernia or adhesion: late presentation; UGI/CT; surgical exploration if not resolving.
Key distinction: POPF vs. bile leak — both elevate drain output and cause fever, but drain amylase is high in POPF, drain bilirubin is high in bile leak. Order both on any cloudy/bilious drain.
Board pearl: Free air on CT after POD 7 is always pathologic (postop pneumoperitoneum should resolve by POD 5–7) — assume anastomotic dehiscence and act accordingly.
— Pulmonary embolism: tachycardia, hypoxia, pleuritic chest pain on POD 3–10; high baseline risk in pancreatic cancer surgery; CTPA if stable; consider despite recent surgery — risk of missed PE > bleed risk.
— Pneumonia / aspiration: especially with DGE, NG dependence; CXR, sputum culture.
— C. difficile colitis: profuse diarrhea after broad-spectrum antibiotics; stool PCR; oral vancomycin or fidaxomicin.
— Catheter-associated UTI and central line-associated bloodstream infection (CLABSI): remove unnecessary lines/Foley early.
— Myocardial infarction (type 2): demand ischemia in elderly with anemia/tachycardia; troponin, ECG.
— Atrial fibrillation with RVR: common post major abdominal surgery; rate control with beta-blocker, anticoagulation decision balances bleeding risk.
— Adrenal insufficiency: chronic steroid users; cosyntropin or empirical hydrocortisone in refractory hypotension.
— Transfusion reactions / TRALI.
— Drug fever / reaction: beta-lactams classic; eosinophilia clue.
— Acalculous cholecystitis: rare since gallbladder removed in Whipple, but cholangitis from HJ stricture mimics.
— Hyperglycemic crisis in new type 3c DM.
Step 3 management: A post-Whipple patient with new tachycardia and hypoxia on POD 5 — even with a "valid surgical explanation" — still needs CTPA. Don't anchor; the post-op pancreatic cancer patient has Virchow's triad maxed.
Key distinction: Postoperative atrial fibrillation usually does not require long-term anticoagulation if it converts within 48 h and CHA2DS2-VASc is low — but persistent post-op AF >48 h with elevated CHA2DS2-VASc → anticoagulate per AF guidelines, timing individualized with surgical team.
— PPI (pantoprazole 40 mg daily) × 3–6 months minimum for marginal ulcer prophylaxis.
— Enoxaparin 40 mg SC daily × 28 days post-discharge for cancer surgery VTE prophylaxis.
— Pancreatic enzymes (PERT): pancrelipase 40,000–50,000 units with meals, half-dose with snacks; titrate to stool quality and weight.
— Fat-soluble vitamins (ADEK) supplementation; check levels at 3–6 months.
— Insulin if diabetic; glucose log and endocrine follow-up.
— Multivitamin, vitamin B12 (terminal ileum spared but absorption may suffer), iron if anemic.
— Stool softener during opioid taper; opioid taper plan documented.
— mFOLFIRINOX × 6 months is standard for fit patients (PRODIGE-24); improves median OS to ~54 months vs. ~35 months with gemcitabine.
— Gemcitabine + capecitabine if not FOLFIRINOX-eligible.
— Start within 8–12 weeks of surgery — delay worsens outcomes.
Board pearl: Initiation of adjuvant chemo within 8–12 weeks of Whipple is a tested benchmark. Excessive postoperative complications that delay chemo are themselves a survival hit.
Step 3 management: PERT dosing failure is usually underdosing — uptitrate before declaring failure; also ensure PPI is co-administered so acid doesn't inactivate enzymes.
— 2 weeks post-discharge: wound check, symptom review, lab recheck (CBC, BMP, LFTs, glucose), medication reconciliation, pain/opioid taper.
— 4–6 weeks: surgical clinic; address DGE, weight, PERT titration; plan to start adjuvant chemo.
— Every 3 months × 2 years, then every 6 months × 3 years, then annually: oncology surveillance with H&P, CA 19-9, and CT chest/abdomen/pelvis (NCCN).
— Annual DEXA (osteoporosis risk from fat malabsorption).
— HbA1c every 3 months if diabetic; annual fasting glucose if not.
— Vitamin ADEK levels at 3, 6, 12 months, then annually.
— Weight trend (target stabilization within 5–10% of preop weight by 6 months).
— Stool frequency/character (steatorrhea = under-PERT).
— Glycemic control logs.
— LFTs (rising ALP/bilirubin → HJ stricture workup with MRCP).
— Prehab and rehab with PT/OT improve outcomes — emphasize early mobilization, resistance training.
— Nutrition counseling: high-protein, small frequent meals; MCT oil for chyle leak history.
— Psychosocial: depression and anxiety common; screen with PHQ-9; refer for survivorship support.
— Smoking cessation: pharmacotherapy + counseling; never too late.
— Survivorship care plan documenting surgery, chemo, surveillance schedule, late-effect monitoring.
Step 3 management: "What is the recommended postoperative pancreatic cancer surveillance?" → H&P + CA 19-9 + CT every 3–6 months for the first 2 years, then less frequently — not PET, not MRI alone.
Board pearl: A rising CA 19-9 with normal imaging warrants closer interval surveillance (3 months) and consideration of PET-CT — recurrence often biochemical before radiographic.
— Must disclose mortality (1–5% at high-volume centers, higher elsewhere), morbidity (30–50%), specific risks of POPF, hemorrhage, leak, DGE, diabetes, exocrine insufficiency, need for adjuvant chemo, and possibility of intraoperative findings precluding resection (abort rate ~10–20%).
— Discuss alternatives: neoadjuvant therapy, palliative options, second opinion.
— Volume-outcome disclosure: ethically, a low-volume center surgeon should disclose center volume or refer; this is a Step 3 patient-safety touchstone.
— Use frailty assessment, life expectancy, and patient values; document goals-of-care discussion.
— Avoid surgical ageism, but recognize when surgery's burden outweighs benefit.
— Medication reconciliation at discharge (anticoagulant duration, PERT dosing, opioid taper, insulin) is a top source of preventable readmission.
— Structured handoff to primary care and oncology with explicit follow-up appointments before discharge reduces readmissions.
— Teach-back method for PERT timing, glucose monitoring, drain care (if going home with drain), signs of complications.
— Surgical site infections, VTE, mortality, and readmissions are reportable to NSQIP and influence value-based reimbursement.
— Never events (retained foreign body, wrong-site surgery): time-outs and counts are non-negotiable.
Step 3 management: A 78-year-old with resectable pancreatic head cancer at a community hospital that does 4 Whipples/year — the most appropriate next step is referral to a high-volume regional center, not proceeding locally. Volume-outcome disclosure is an ethical obligation.
Board pearl: Inadequate discharge medication reconciliation is one of the most common roots of readmission — Step 3 loves "structured discharge with teach-back" as the right answer.
Board pearl: "Cloudy brown drain on POD 4 with fever and tachycardia" = POPF until proven otherwise → drain amylase, CT, continue drainage, antibiotics if febrile.
Key distinction: Bleeding within 24 h = technical; bleeding after 24 h = erosive from a leak/abscess — totally different management.
Step 3 management: When two answers look right, pick the outpatient management, secondary prevention, or transition-of-care answer over the inpatient one — that's the Step 3 lens.
Board pearl: "POD X + drain change + vitals delta" pattern = a Whipple complication stem 95% of the time.
Whipple complications are dominated by postoperative pancreatic fistula, delayed gastric emptying, and the lethal sentinel-bleed/pseudoaneurysm axis — recognized by drain fluid trends and trajectory deviations, managed with IR-first strategies, and prevented from killing the patient by anticipatory monitoring, structured discharge, and early adjuvant chemotherapy.
Board pearl: On Step 3, the post-Whipple vignette tests pattern recognition (POD timing + drain character + vitals delta), the procedural reflex (CTA + IR before OR), and the longitudinal lens (PERT, adjuvant chemo, surveillance) — answer all three layers correctly and you cannot miss the question.
Step 3 management: Always escalate to drain amylase + contrast CT + surgical reconsult for any post-Whipple trajectory deviation — the answer is rarely "reassure and observe."